Rubicon Research Limited announced key outcomes from its Board of Directors meeting held on February 3, 2026. The board approved the appointment of Dr. Pradnya Saravade as an Additional-Independent Woman Director for a three-year term, effective February 3, 2026, to February 2, 2029, subject to member approval. Additionally, the board noted the resignation of Mr. Anand Agarwal as a Non-Executive Director, effective at the close of business on February 3, 2026. M/s. BNP & Associates has been approved and recommended as the Secretarial Auditor for FY 2025-26 and the subsequent four years through FY 2029-30, also pending member approval. Furthermore, the company granted in-principle approval for the merger of its wholly-owned subsidiary, KIA Health Tech Private Limited, with Rubicon Research Limited. This merger is subject to board approval of the scheme of arrangement, regulatory approvals, and other administrative formalities. The board meeting commenced at 3:00 PM IST and concluded at 4:30 PM IST.
